Skip to main content
Market intelligence
OKURSector not reported

OnKure Therapeutics, Inc. insider activity

In the last 90 days, no corporate insiders reported open-market purchases.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Jun 22, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Jun 22, 2026Jason A. LeveroneChief Financial OfficerSale303$4.40$1,332
Jun 22, 2026Nicholas A SaccomanoPresident and CEOSale86$4.40$378.08